HER2-positive early stage breast cancer

December 6, 2019

CHMP Favors Kadcyla Approval in EU for Certain HER2-positive Early Breast Cancer Patients

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that Kadcyla (ado-trastuzumab emtansine) be approved as an adjuvant (post-surgery) treatment for certain HER2-positive ... Read more

July 16, 2018

Trial Testing Need for Radiotherapy in HER2-Positive Breast Cancer Enrolling Patients

News

Researchers at The University of Kansas Cancer Center have launched a clinical trial evaluating the need for radiation therapy after surgical removal of an aggressive type of breast cancer that ... Read more

March 2, 2018March 2, 2018

EMA’s CHMP Issues Negative Opinion of Neratinib as Added Therapy in Early Stage HER2-positive Breast Cancer

News

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion of neratinib as an extended adjuvant treatment of early stage, HER-2 positive breast cancer. ... Read more

April 11, 2017April 11, 2017